Overcome Common Pre-Filled Syringe Challenges Through Partnership

As demand for biologic drugs surges, the pre-filled syringe (PFS) market is experiencing unprecedented growth, promising enhanced patient safety and reduced manufacturing costs. But while PFS offers clear advantages over traditional vial systems, it brings its own complex challenges — particularly when it comes to high-viscosity formulations.

This article explores how Contract Development and Manufacturing Organizations (CDMOs) like Curia are addressing these issues through customized engineering, advanced equipment calibration, and rigorous compliance protocols. From managing the intricacies of controlled substance reconciliation to navigating the trade-offs between glass and polymer syringes, Curia shares insights from the front lines of PFS innovation.

Learn how collaborative problem-solving, analytical expertise, and flexible service models are shaping the future of drug delivery. Whether you’re developing a new biologic or seeking to optimize an existing product, this article reveals why a one-size-fits-all approach simply won’t do — and how Curia is helping its partners succeed in a rapidly evolving landscape.